A Nationwide Survey of Knowledge of and Compliance with Cancer Pain Management Guidelines by Korean Physicians

Do Yeun Kim; Jin Seok Ahn; Kyung Hee Lee; Young Chul Kim; Juneyoung Lee; Si-Young Kim

doi:10.4143/crt.2014.46.2.131

Articles

Page Path: HOME > Cancer Res Treat > Volume 46(2); 2014 > Article

Original Article A Nationwide Survey of Knowledge of and Compliance with Cancer Pain Management Guidelines by Korean Physicians: Do Yeun Kim, MD¹, Jin Seok Ahn, MD², Kyung Hee Lee, MD³, Young Chul Kim, MD⁴, Juneyoung Lee, PhD⁵, Si-Young Kim, MD⁶; Cancer Research and Treatment : Official Journal of Korean Cancer Association 2014;46(2):131-140.
DOI: https://doi.org/10.4143/crt.2014.46.2.131
Published online: April 15, 2014

¹Department of Internal Medicine, Dongguk University Ilsan Hospital, Dongguk University College of Medicine, Goyang, Korea.

²Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

³Department of Internal Medicine, Yeungnam University College of Medicine, Daegu, Korea.

⁴Department of Internal Medicine, Chonnam National University Hwasun Hospital, Chonnam National University Medical School, Hwasun, Korea.

⁵Department of Biostatistics, Korea University College of Medicine, Seoul, Korea.

⁶Department of Internal Medicine, Kyung Hee University Hospital, Kyung Hee University School of Medicine, Seoul, Korea.

Correspondence: Si-Young Kim, MD. Division of Hematology and Medical Oncology, Department of Internal Medicine, Kyung Hee University Hospital, 26 Kyungheedae-ro, Dongdaemun-gu, Seoul 130-701, Korea.
Tel: 82-2-958-8721, Fax: 82-2-959-7192, sykim@khu.ac.kr

• Received: March 15, 2013 • Accepted: June 25, 2013

This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

12,820 Views
106 Download
6 Web of Science
7 Crossref
5 Scopus

prev next

Full Article

Download PDF

Abstract

Purpose
Although cancer pain is prevalent, under-treatment still remains a problem. Knowledge of and compliance with guidelines for management of cancer pain were analyzed for exploration of physician-related barriers to cancer pain management. In addition, physicians' knowledge and its correlation with cancer pain control were audited.
Materials and Methods
From July 8 to December 2, 2010, a nationwide survey of house staff enquired about their knowledge of cancer pain control guidelines, and the medical records of patients under their care were analyzed.
Results
In total, 180 physicians participated in the study. Their average score for knowledge was 14.6 (range, 7 to 19; maximum possible, 20). When the knowledge score was divided into low, medium, and high scores, patients receiving care from physicians with high levels of knowledge tended to have better cancer pain control (p<0.001). Of the total patients with severe pain, 19.5% were not prescribed strong opioids, and 40% were not prescribed any medication for breakthrough pain.
Conclusion
Physicians' knowledge of guidelines for control of cancer pain showed an association with improvement of pain management. Overall adherence to the guidelines was lacking. Continuous interventions such as education and audits regarding cancer pain control guidelines for physician are needed.
Key words: Pain, Neoplasms, Knowledge, Analgesics, Guideline, Compliance

Introduction

Chronic pain is the most frequent and troubling symptom in cancer patients. Prevalence rates from 33% during curative treatment to 64% in advanced/metastatic/terminal disease have been reported, with a pooled prevalence >50% for all cancer types [1]. However, the optimal pharmacotherapy is well established and sophisticated guidelines for control of cancer pain have become a standard tool in clinical practice, therefore, chronic cancer pain should be relieved in more than 90% of patients [2,3]. Although adequate and effective analgesic prescription is the key to control of cancer pain, a recent review reported that 43% of cancer patients had a negative pain management index score, meaning that prescription potency is inadequate when the patient's reported level of pain is compared with the intensity of the analgesic therapy [4]. The situation in Korea is similar. Despite increased attention to management of cancer pain, 47.4% of patients with severe pain did not receive adequate analgesia [5].

Why is there a difference between the ideal state and the real-world situation in cancer pain control? A recent review of the relevant literature identified several principal barriers to adequate management of cancer pain, including knowledge deficits, inadequate pain assessment, and misconceptions about pain on the part of both patients and professionals [6]. As expected, professional-related barriers included insufficient knowledge and poor evaluation of pain, lack of adherence to pain management guidelines, too much concern about addiction, and a low priority given to cancer pain control in treatment. Above all, several studies have reported that medical staff frequently have erroneous knowledge and simply do not pay attention to pain assessment [7,8,9,10]. Other factors such as reluctance to prescribe opioids, lack of access to opioids, and excessive regulation to prevent over-prescribing of opioids were demonstrated less frequently.

Thus, there is an urgent need for development of interventions that increase knowledge and adherence to existing cancer pain control guidelines for professionals. Studies on pain education programs for professionals have underscored the inadequacy of pain treatment; indeed, findings of three studies showed no difference in the decrease in patient pain between the intervention and control groups [11,12,13]. However, these studies targeted nurses. Because physicians are primarily responsible for prescribing medications, education of physicians in cancer pain control could have a greater impact. Kim et al. [14] reported on the effects of a pain education program for primary physicians who used the National Comprehensive Cancer Network (NCCN) guidelines for adult cancer pain. After receiving education, they classified physicians according to high and low guideline-observance groups and estimated the time to reach avisual analog scale pain score of <3. It took three days in the high guideline-observance group, but six days in the low observance group. These findings highlight the significance of continuous efforts to improve physician knowledge and audits of adherence to cancer pain management guidelines in the clinic.

In this study, we examined the knowledge of physicians who care primarily for cancer patients and their compliance with guidelines for management of cancer pain in clinical practice. In addition, we analyzed the correlation between a physician's level of pain management and the adequacy of pain control.

Materials and Methods

This study was approved by the institutional review board of each participating hospital. From July 8 to December 2, 2010, this study was conducted nationwide by means of a house staff survey and retrospective review of medical records.

The survey instrument was developed by the palliative care committee of the Korean Cancer Study Group. Four medical oncologists were actively involved in the process. Feedback and reviews were exchanged several times between investigators and protocol developers. Finally, 20 items were selected for evaluation of physicians' knowledge of pain management.

A survey of knowledge of NCCN adult cancer pain guidelines (ver. 1. 2011) was conducted among house staff responsible for the care of cancer patients. The questionnaire asked for information regarding the physician's age, gender, and practice setting. Of the 20 questions, 12 were answered with 'yes' or 'no,' while the other eight questions required selection of a single answer from among five multiple choice statements. The eight multiple-choice questions included three questions regarding treatment recommendations for hypothetical patients with challenging situations and five questions concerning specific pain management practices such as basic principles for the use of strong opioids and management of opioid side effects. Completion of the survey required 30 minutes, and it was intended to be answered before beginning the medical chart review.

The medical charts of patients under the care of physicians who completed the survey were reviewed retrospectively with respect to pain management three days prior to the date of the physician survey. The inclusion criteria were hospitalized patients who had ever complained of cancer pain, were receiving treatment from house staff who had completed the physician survey, had been hospitalized for more than four days, were over 20 years of age, and provided written informed consent.

Information regarding pain and pain management was obtained from medical records. The one-page data sheet covered five issues: 1) patient demographic data, including age, gender, diagnosis, stage, and Eastern Cooperative Oncology Group performance status scale; 2) pain assessment: severity, nature, and site; 3) management of chronic pain: drug composition and dose; 4) management of breakthrough pain: drug composition and dose; and 5) administration of drugs to counter the adverse effects of opioids.

Demographic characteristics of patients are presented as mean (standard deviation) or numbers and percentages. Physicians' knowledge of clinical practice guidelines was evaluated using 12 true/false questions; responses are presented as numbers and percentages. Physicians' responses regarding treatment strategies for challenging clinical scenarios are summarized as percentages. The linear association between pain severity classified using the numeric rating scale (NRS) on days -3 and 0 was evaluated using the Cochran-Mantel-Haenszel test. The chi-squared test was used to determine whether the change in the NRS level from day -3 to day 0 and the patient pain severity at day 0, grouped as none, mild, moderate, or severe, differed according to physician's level of knowledge. The grouping of NRS levels was based on the categorical pain scale of the NCCN guidelines: none (0), mild (1-3), moderate (4-6), or severe (7-10).

All statistical analyses were performed using SAS ver. 9.12 (SAS Institute Inc., Cary, NC). All p-values are two-tailed, and values of <0.05 were considered to indicate statistical significance.

Results

1. Subjects' characteristics

Among the 180 physicians who completed the survey, 95 (53.4%) were male. Their mean age was 29.6 years; 52.8% practiced in oncology wards, while the others practiced in hospice wards or other departments. The pain management audit was performed in 1,808 patients. Patient characteristics are shown in Table 1.

2. Evaluation of knowledge regarding clinical practice guidelines

The distribution of knowledge scores is shown in Fig. 1. The average score for knowledge was 14.6 out of a maximum of 20 (range, 7 to 19). The 12 true/false questions and responses are listed in Table 2. Responses for the three hypothetical case scenarios and the remaining five questions, which required selection of one correct response from among multiple statements, are shown in Appendix 1.

The physicians answered the 12 true/false questions correctly 69.4% to 98.3% of the time. These questions concerned basic knowledge regarding cancer pain management. The questions most frequently answered incorrectly were those regarding a clinical scenario with equianalgesic dosing for opioid rotation (correct answer percentage, 12.8%), general principles of the adverse effects of opioids (correct answer percentage, 47.2%), and management of pain in opioid-naïve patients (correct answer percentage, 51.1%).

For interpretation of pain severity depending on a physician's knowledge level, physicians were divided into high, medium, and low subgroups. Cut-off values were set at 13 and 16 of the total of 20 points. The division by knowledge level-low, medium, and high-was 26.1% (47/180), 37.8% (68/180), and 36.1% (65/180), respectively.

3. Adherence in clinical practice to cancer pain management guidelines

Assessments performed included an audit of pain assessment records, medical records of pain assessment, and medications used for control of continuous and/or breakthrough pain.

The audit of pain assessment records showed that pain severity was recorded in 30.1% of cases, whereas other elements such as site of pain, nature of pain, and side effects of opioids were rarely recorded by the physician, in less than 5% of cases. Contrary to the World Health Organization (WHO) step-ladder analgesic guidelines, strong opioids were not prescribed to 19.5% of patients who complained of severe cancer pain. Pro re nata (PRN) prescriptions for control of breakthrough pain were not given to 40% of patients. Because the data were collected over four days, the parameters listed above were assessed on day 0; nevertheless, the results in terms of not prescribing strong opioids or PRN medications were similar on all days.

4. Pain severity and impact of physician knowledge

Based on the retrospective observations, the percentage of poorly controlled pain (NRS level higher than 4) during the three days before the survey was 33.2%. The average time for reduction of moderate and severe pain to mild pain was 1.74±0.8 days. Data on the change in pain severity from three days before the chart review day to the start day and its correlation with physician knowledge are shown in Table 3 and Fig. 2. Of those who complained of severe pain on day -3, 24.1% remained in severe pain on day 0. Patients under the care of physicians in the high-knowledge group tended to show a greater decrease in NRS level over time (p<0.001). A significant correlation was observed between pain severity on day 0 and physician's level of knowledge (Fig. 3) such that patients under the care of physicians with a high level of knowledge of cancer pain control tended to experience better cancer pain control. This finding was consistent during the four days of the medical chart review. Because pain severity was recorded by physicians only 30.1% of the time, nursing charts were also consulted. When both records were available for one patient, we found no significant difference in the NRS score between the physician record and the nursing chart. Thus, when both a physician record and a nursing chart were available for the same time period, we chose the physician record.

Discussion

The current nationwide study demonstrated that many physicians lack knowledge of and compliance with cancer pain guidelines. In addition, the changes in and distribution of NRS levels were affected by the physicians' knowledge, suggesting that greater physician knowledge would translate to better patient outcomes.

Control of cancer pain has shown gradual improvement owing to more effective medications, better practice guidelines, and greater attention to pain management. Nevertheless, because pain management is inadequate in real-world situations, there remains significant room for further improvement [1].

Physician, patient, and regulatory issues are all well-known barriers to adequate pain management [6]. Physicians are primarily responsible for prescribing opioids and play a role in educating patients. Thus, apart from regulatory issues, overcoming physician barriers would seem to be an effective way of achieving cancer pain control. Many studies have supported the notion that professionals may possess inadequate knowledge and have concluded that a physician's inadequate assessment and knowledge of cancer pain contribute to poor pain management [15,16,17].

In the current study, we evaluated physicians' knowledge of cancer pain guidelines and its impact on severity of patients' pain. Although the overall score for knowledge was relatively high and almost 90% of physicians responded correctly to the true/false question on basic knowledge of cancer pain management, 27.8% answered no to a question regarding whether pain control was a priority. Indeed, most medical oncologists would readily perform active diagnostic imaging and/or anticancer treatment before pain control. However, many patients do not have to endure pain during evaluation and/or treatment. Pain control should be administered simultaneously with active evaluation/anticancer treatment. Increasing evidence in oncology of a link between survival and pain control supports the importance of this point [18]. Regarding questions with one correct answer among multiple choices, the three questions that were answered incorrectly most often concerned adequate pain control. Regarding equianalgesic dosing for opioid rotation, only 12.8% of responders answered correctly. The two other questions that were only infrequently answered correctly were queried general principles of the adverse effects of opioids (47.2%) and management of pain in opioid-naïve patients (51.1%). The correct answer for adequate breakthrough dosing was selected by only 58.3% of responders. These weak points were consistent with those of a study of knowledge of cancer pain management among physicians in British Columbia [19]. According to that study, equianalgesic dosing (68%) and adequate breakthrough dosing (45%) were the questions most commonly answered incorrectly.

Adherence to cancer pain guidelines by physicians on the wards is another key issue. Their competency in terms of knowledge, positive attitude, and skills under test conditions does not always translate into actual practice [20,21]. Major reasons for this may include time limitations on pain management due to busy rounds schedules and disparities between the tested and the actual circumstances.

A review of medical charts showed that strong opioids were not prescribed to 19.5% of patients with severe cancer pain, and 40% of total patients were not prescribed any medication for breakthrough pain. These data are surprising in comparison with the answers to the related survey questions. Indeed, 82.8% of responders answered "false" to the statement that non-narcotic medicines should be tried first even for severe cancer pain. In addition, 88.3% of physicians answered "yes" to the question of whether patients should have access to immediate-release opioids and be allowed to use them as needed for management of severe pain. Our findings are not unusual. Thota et al. [22] reported that only 48% of opioid prescriptions for chronic cancer pain were consistent with the WHO pain relief ladder, and only half of patients reporting severe pain were prescribed morphine.

Initially, we attempted to use the medication-assessment tool for cancer pain management (MAT-CP) for assessment of adherence to medication for control of cancer pain [23]. However, several criteria could not be analyzed consistently among patients. The representative parameters evaluated in this tudy were pain assessment as documented in the medical notes, WHO ladder drug combinations, and PRN prescriptions for intermittent pain. In a recent study using MAT-CT from the United Kingdom, overall adherence to guidelines was good, with low adherence (<50%) for nine criteria: documentation for pain intensity, characteristics, and etiology; pain intensity assessed before and after starting continuous opioids; normal-release preparation preferred; had morphine first; pain intensity recorded on follow-up pain therapy; and care issues for bone metastases, co-prescribing bisphosphonates [24]. Further work on the adequacy of opioid prescriptions, together with care issues such as side-effect management, is clearly needed in Korea.

Above all, our findings showed that better knowledge of cancer pain management resulted in greater reduction of patient pain severity. To date, use of five interventions for pain management in hospitalized cancer patients-professional and patient education, institution of regular assessments, audits of pain results and feedback to clinical staff, computerized decisional support systems, and specialist-level pain consultation services-has not led to improvement of severity of patient pain, although patient satisfaction was increased. However, the professional education was aimed primarily at nurses and did not specifically target physicians. Taking that into consideration, our finding is unique in suggesting that greater physician knowledge of cancer pain management would result in greater pain relief for patients.

This study has several limitations. First, the responding physicians may not be representative. In particular, knowledge and prescribing preferences were based primarily on medical oncologists. The findings might have been different had the survey included physicians of other specialties. Second, we were unable to determine correlation between physician knowledge levels and the extent of adherence to pain knowledge guidelines. As mentioned previously, we relied on clinical documentation obtained retrospectively from patient medical records. Thus, the information was not sufficient to evaluate correlation between a high level of knowledge and high adherence to guidelines.

Finally, further investigations regarding to determine whether physician knowledge is reflected in actual clinical practice and affects improvement of patient pain and patient satisfaction, and, ultimately, outcome should be conducted.

Conclusion

Our data suggest that systematic education and adherence to practice guidelines for management of cancer pain should be encouraged in all physicians responsible for care of patients suffering cancer pain. In addition, audits of adherence to cancer pain management guidelines should be conducted in order to ensure good pain management outcomes.

Acknowledgements

Acknowledgments

We would like to thank all institutions and physicians participating in this survey. Participating institutions are listed as follows.

Ajou University Medical Center, Asan Medical Center, Baptist Hospital, Bobath Memorial Hospital, Bohun Hospital (Daegu), Bohun Hospital (Gwangju), Bohun Hospital (Seoul), Bundang CHA Hospital, Bundang Jesaeng Hospital, Busan Medical Center, Busan St. Mary's Hospital, Cheongju St. Mary's Hospital, Chonbuk National University Hospital, Chonnam National University Hwansun Hospital, Chosun University Hospital, Chung-Ang University Hospital, Chungbuk National University Hospital, Chungnam National University Hospital, Daegu Fatima Hospital, Daegu Catholic University Medical Center, Dankook University Hospital, Dong-A University Hospital, Dongguk University Ilsan Hospital, Gyeongsang National University Hospital, Eulji University Hospital (Daejeon), Eulji University Hospital (Seoul) Medical Center, Ewha Womens University Mokdong Hospital, Gachon University Gil Hospital, Good Samaritan Hospital, Korea Cancer Center Hospital, Hanil Hospital, Hallym University Medical Center, Hanyang University Hospital, Inha University Hospital, Inje University Haeundae Paik Hospital, Inje University Sanggye Paik Hospital, Inje University Seoul Paik Hospital, Inje University Pusan Paik Hospital, Kangbuk Samsung Hospital, Keimyung University Dongsan Medical Center, Konkuk University Medical Center, Konyang University Hospital, Korea University Anam Hospital, Korea University Guro Hospital, Kosin Universiy Gospel Hospital, Kyung Hee University Hospital at Gangdong, Kyungpook National University Hospital, Medi-Yin Hospital, Myongji Hospital, National Health Insurance Service Ilsan Hospital, Pusan National University Hospital, Pusan National University Yangsan Hospital, SAM Anyang Hospital, Saemyung Hopsital, Samgsung Medical Center, Seoul Medical Center, Seoul Metropolitan Seobuk Hospital, Seoul National University Bundang Hospital, Severance Hospital, SMG-SNU Boramae Medical Center, Soonchunhyang University Hospital, Soonchunhyang University Bucheon Hospital, Soonchunhyang University Cheonan Hospital, St. Carollo Hospital, The Catholic University of Korea Bucheon St. Mary's Hospital, The Catholic University of Korea Daejeon St. Mary's Hospital, The Catholic University of Korea Incheon St. Mary's Hospital, The Catholic University of Korea Seoul St. Mary's Hospital, The Catholic University of Korea Yeouido St. Mary's Hospital, The Catholic University of Korea St. Paul's Hospital, The Catholic University of Korea Uijeongbu St. Mary's Hospital, Wonju Christian Hospital, Wonkwang University Hospital, Yeungnam University Hospital.

NOTES

This research was supported financially by grants from the Johnson & Johnson family of companies, whose role was restricted and did not involve providing assistance to the investigators in the conception, conduct, and analysis of the study.

REFERENCES

1. van den Beuken-van Everdingen MH, de Rijke JM, Kessels AG, Schouten HC, van Kleef M, Patijn J. Prevalence of pain in patients with cancer: a systematic review of the past 40 years. Ann Oncol. 2007;18:1437–1449. PMID: 17355955Article PubMed
2. Benedetti C, Brock C, Cleeland C, Coyle N, Dube JE, Ferrell B, et al. NCCN practice guidelines for cancer pain. Oncology (Williston Park). 2000;14:135–150. PMID: 11195407PubMed
3. World Health OrganizationCancer pain relief: with a guide to opioid availability. 2nd ed. Geneva: World Health Organization; 1996.
4. Deandrea S, Montanari M, Moja L, Apolone G. Prevalence of undertreatment in cancer pain. A review of published literature. Ann Oncol. 2008;19:1985–1991. PMID: 18632721Article PubMed PMC
5. Hong SH, Roh SY, Kim SY, Shin SW, Kim CS, Choi JH, et al. Change in cancer pain management in Korea between 2001 and 2006: results of two nationwide surveys. J Pain Symptom Manage. 2010;9. 24[Epub ahead of print]Article
6. Oldenmenger WH, Sillevis Smitt PA, van Dooren S, Stoter G, van der Rijt CC. A systematic review on barriers hindering adequate cancer pain management and interventions to reduce them: a critical appraisal. Eur J Cancer. 2009;45:1370–1380. PMID: 19201599Article PubMed
7. Yu S, Wang XS, Cheng Y, Yang J, Cleeland CS. Special aspects of cancer pain management in a Chinese general hospital. Eur J Pain. 2001;5(Suppl A):15–20. PMID: 11798212Article PubMed
8. Ger LP, Ho ST, Wang JJ. Physicians' knowledge and attitudes toward the use of analgesics for cancer pain management: a survey of two medical centers in Taiwan. J Pain Symptom Manage. 2000;20:335–344. PMID: 11068155Article PubMed
9. Wolfert MZ, Gilson AM, Dahl JL, Cleary JF. Opioid analgesics for pain control: wisconsin physicians' knowledge, beliefs, attitudes, and prescribing practices. Pain Med. 2010;11:425–434. PMID: 20002590Article PubMed
10. Kim MH, Park H, Park EC, Park K. Attitude and knowledge of physicians about cancer pain management: young doctors of South Korea in their early career. Jpn J Clin Oncol. 2011;41:783–791. PMID: 21502282Article PubMed
11. de Rond ME, de Wit R, van Dam FS, van Campen BT, den Hartog YM, Klievink RM. A pain monitoring program for nurses: effects on nurses' pain knowledge and attitude. J Pain Symptom Manage. 2000;19:457–467. PMID: 10908826Article PubMed
12. Francke AL, Luiken JB, de Schepper AM, Abu-Saad HH, Grypdonck M. Effects of a continuing education program on nurses' pain assessment practices. J Pain Symptom Manage. 1997;13:90–97. PMID: 9095566Article PubMed
13. Ger LP, Chang CY, Ho ST, Lee MC, Chiang HH, Chao CS, et al. Effects of a continuing education program on nurses' practices of cancer pain assessment and their acceptance of patients' pain reports. J Pain Symptom Manage. 2004;27:61–71. PMID: 14711470Article PubMed
14. Kim HT, Koh KW, Kim YM, Kang MS, Noh HS, Kim HR, et al. Pain management based on NCCN guideline in patients with lung cancer. Tuberc Respir Dis. 2009;67:221–225. Article
15. Elliott TE, Elliott BA. Physician attitudes and beliefs about use of morphine for cancer pain. J Pain Symptom Manage. 1992;7:141–148. PMID: 16967581Article PubMed
16. Elliott TE, Murray DM, Elliott BA, Braun B, Oken MM, Johnson KM, et al. Physician knowledge and attitudes about cancer pain management: a survey from the Minnesota cancer pain project. J Pain Symptom Manage. 1995;10:494–504. PMID: 8537691Article PubMed
17. Weinstein SM, Laux LF, Thornby JI, Lorimor RJ, Hill CS Jr, Thorpe DM, et al. Physicians' attitudes toward pain and the use of opioid analgesics: results of a survey from the Texas Cancer Pain Initiative. South Med J. 2000;93:479–487. PMID: 10832945Article PubMed
18. Temel JS, Greer JA, Muzikansky A, Gallagher ER, Admane S, Jackson VA, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med. 2010;363:733–742. PMID: 20818875Article PubMed
19. Gallagher R, Hawley P, Yeomans W. A survey of cancer pain management knowledge and attitudes of British Columbian physicians. Pain Res Manag. 2004;9:188–194. PMID: 15605132Article PubMed
20. Rethans JJ, Sturmans F, Drop R, van der Vleuten C, Hobus P. Does competence of general practitioners predict their performance? Comparison between examination setting and actual practice. BMJ. 1991;303:1377–1380. PMID: 1760606Article PubMed PMC
21. Eccles M, Ford GA, Duggan S, Steen N. Are postal questionnaire surveys of reported activity valid? An exploration using general practitioner management of hypertension in older people. Br J Gen Pract. 1999;49:35–38. PMID: 10622014PubMed PMC
22. Thota RS, Jain P, Bakshi SG, Dhanve CN. Opioid-prescribing practices in chronic cancer pain in a tertiary care pain clinic. Indian J Palliat Care. 2011;17:222–226. PMID: 22346047Article PubMed PMC
23. Hakonsen GD, Hudson S, Loennechen T. Design and validation of a medication assessment tool for cancer pain management. Pharm World Sci. 2006;28:342–351. PMID: 17120130Article PubMed
24. Hakonsen GD, Strelec P, Campbell D, Hudson S, Loennechen T. Adherence to medication guideline criteria in cancer pain management. J Pain Symptom Manage. 2009;37:1006–1018. PMID: 19500723Article PubMed

Appendix

Appendix 1

Fig. 1

Distribution of physicians' scores for knowledge of cancer pain guidelines.

Fig. 2

Correlation between changes of numeric rating scale (NRS) level and level of physician knowledge (p<0.0001).

Fig. 3

Correlation between pain severity and level of physician knowledge (missing data, n=338) (p<0.0001).

Table 1

Demographic data of cancer patients

Patient characteristic	No. (%) (n=1,808)
Gender (%)^a)
Male	1,040 (57.5)
Female	756 (41.8)
Age (yr)
Mean±SD (range)	59.47±78 (12-63)
Current active anticancer treatment (%)	1,059 (58.6)
Metastatic disease (stage IV)	1,153 (76.2)
ECOG performance status
0-1	572 (31.6)
2	406 (22.5)
3	269 (14.9)
4	78 (4.3)
Cancer diagnosis^b)
Lung	353 (20.4)
Stomach	243 (14.1)
Colorectal	213 (12.3)
Pancreas	101 (5.9)
Breast	99 (5.7)
Hematological (MM, leukemia, lymphoma)	192 (11.1)
Others	526 (30.5)

SD, standard deviation; ECOG, Eastern Cooperative Oncology Group; MM, multiple myeloma.

^a) Missing data (n=12),

^b) Multiple responses are omitted.

Table 2

Responses to true/false knowledge questions^a)

Statement	True	False	Don’t know
Most cancer-related pain can be controlled by medication	161 (89.4)	16 (8.9)	2 (1.1)
If a cancer patient complains of pain, the pain should be treated as soon as possible before or at the same time as establishing the cancer treatment plan	125 (69.4)	50 (27.8)	5 (2.8)
Non-narcotic medicines should be tried first for even severe cancer-related pain and narcotic medicine should be tried if they are not effective	30 (16.7)	149 (82.8)	1 (0.6)
Addiction to narcotic pain killers is likely if narcotic medicine is used for cancer-related pain	18 (10.0)	160 (88.9)	2 (1.1)
If a higher dose of narcotic pain killers is required for cancer-related pain, the probability of addiction increases	6 (3.3)	173 (96.1)	1 (0.6)
Cancer-related pain can be controlled with narcotic pain killers, but the patient’s life span might be reduced as a result	3 (1.7)	173 (96.1)	3 (1.7)
When switching from injected morphine to oral morphine, the dose should remain the same	20 (11.1)	158 (87.8)	2 (1.1)
When tolerance develops for narcotic pain killers, the dose should be reduced or medication should be stopped	11 (6.1)	158 (87.8)	11 (6.1)
Patients should have immediate-release opioids and use them as needed when the pain becomes severe	159 (88.3)	20 (11.1)	1 (0.6)
Narcotic pain killers do not have ceiling effects and the dose can be increased without an upper limit	148 (82.2)	26 (14.4)	5 (2.8)
The use of narcotic pain killers should be reserved for use only when conventional pain killers are no longer effective	2 (1.1)	177 (98.3)	0 (0.0)
Anti-convulsion medicine should be administered additionally for nerve disease-related pain that cannot be controlled to a sufficient level by narcotic pain killers	156 (86.7)	16 (8.9)	7 (3.9)

Values are presented as number (%).

^a) n=180 for doctors who were primary treating patients.

Table 3

Change in pain severity between day .3 and day 0, classified by NRS group^a)

Day 0	Day −3				Total

	None	Mild	Moderate	Severe
None	191 (75.2)	75 (11.4)	27 (7.8)	3 (2.8)	296 (21.7)
Mild	47 (18.5)	503 (76.6)	139 (40.3)	27 (25.0)	716 (52.5)
Moderate	14 (5.5)	72 (11.0)	152 (44.1)	52 (48.2)	290 (21.3)
Severe	2 (0.8)	7 (1.1)	27 (7.8)	26 (24.1)	62 (4.6)
Total	254 (100)	657 (100)	345 (100)	108 (100)	1,364 (100)

Values are presented as number (%). NRS, numeric rating scale.

^a) Missing data (n=444).

Figure & Data

REFERENCES

Citations

Citations to this article as recorded by

Compliance with the breakthrough cancer pain European guidelines and impact on patients' quality of life: an observational prospective study
Paolo Bossi, Tatiana Pietrzyńska, César Margarit Ferri, Irene Mansilla, Valeria Tellone, Sara Fioravanti, Giorgio Di Loreto, Alessandro Comandini
Frontiers in Pain Research.2024;[Epub] CrossRef
A Survey of Knowledge and Barriers of Healthcare Professionals toward Opioid Analgesics in Cancer Pain Management
Nehad M. Ayoub, Malak Jibreel, Khawla Nuseir, Ghaith M. Al-Taani, Manish Gupta
International Journal of Clinical Practice.2022; 2022: 1. CrossRef
Rapid-Onset Opioids for Management of Breakthrough Cancer Pain: Considerations for Daily Practice
Paolo Bossi, Yolanda Escobar, Federico Pea
Frontiers in Pain Research.2022;[Epub] CrossRef
Ozono y COVID-19: bases fisiológicas y sus posibilidades terapéuticas según el estadio evolutivo de la infección por SARS-Cov-2.
Marcos Edgar Fernández Cuadros, María Jesús Albaladejo Florin, Sandra Alava Rabasa, Daiana Peña Lora, Olga Susana Pérez Moro
Revista de la Sociedad Española del Dolor.2021;[Epub] CrossRef
Comparing Methadone Rotation to Consensus Opinion
Michael A. Smith, Kyle C. Quirk, D'Anna C. Saul, Phillip E. Rodgers, Maria J. Silveira
Journal of Pain and Symptom Management.2020; 59(1): 116. CrossRef
Physician’s Attitude toward Treating Breakthrough Cancer Pain in Korea
Min Seok Seo, Jae Yong Shim, Youn Seon Choi, Do Yeun Kim, In Gyu Hwang, Sun Kyung Baek, Jin Young Shin, Juneyoung Lee, Chang Geol Lee
The Korean Journal of Hospice and Palliative Care.2017; 20(1): 18. CrossRef
Commentary on “A Nationwide Survey of Knowledge of and Compliance with Cancer Pain Management Guidelines by Korean Physicians”
Kieran Walsh
Cancer Research and Treatment.2014; 46(4): 425. CrossRef

PubReader
ePub Link

Cite

CITE: export Copy Download Format; Close

Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:

RIS — For EndNote, ProCite, RefWorks, and most other reference management software
BibTeX — For JabRef, BibDesk, and other BibTeX-specific software

Include:

Citation for the content below
Citation and abstract for the content below

A Nationwide Survey of Knowledge of and Compliance with Cancer Pain Management Guidelines by Korean Physicians

Cancer Res Treat. 2014;46(2):131-140. Published online April 15, 2014

DOI: https://doi.org/10.4143/crt.2014.46.2.131

XML Download

Abstract
Introduction
Materials and Methods
Results
Discussion
Conclusion
Acknowledgments
NOTES
REFERENCES
Appendix

A Nationwide Survey of Knowledge of and Compliance with Cancer Pain Management Guidelines by Korean Physicians

Fig. 1 Distribution of physicians' scores for knowledge of cancer pain guidelines.

Fig. 2 Correlation between changes of numeric rating scale (NRS) level and level of physician knowledge (p<0.0001).

Fig. 3 Correlation between pain severity and level of physician knowledge (missing data, n=338) (p<0.0001).

Fig. 1

Fig. 2

Fig. 3

A Nationwide Survey of Knowledge of and Compliance with Cancer Pain Management Guidelines by Korean Physicians

Patient characteristic	No. (%) (n=1,808)
Gender (%)^a)
Male	1,040 (57.5)
Female	756 (41.8)
Age (yr)
Mean±SD (range)	59.47±78 (12-63)
Current active anticancer treatment (%)	1,059 (58.6)
Metastatic disease (stage IV)	1,153 (76.2)
ECOG performance status
0-1	572 (31.6)
2	406 (22.5)
3	269 (14.9)
4	78 (4.3)
Cancer diagnosis^b)
Lung	353 (20.4)
Stomach	243 (14.1)
Colorectal	213 (12.3)
Pancreas	101 (5.9)
Breast	99 (5.7)
Hematological (MM, leukemia, lymphoma)	192 (11.1)
Others	526 (30.5)

Statement	True	False	Don’t know
Most cancer-related pain can be controlled by medication	161 (89.4)	16 (8.9)	2 (1.1)
If a cancer patient complains of pain, the pain should be treated as soon as possible before or at the same time as establishing the cancer treatment plan	125 (69.4)	50 (27.8)	5 (2.8)
Non-narcotic medicines should be tried first for even severe cancer-related pain and narcotic medicine should be tried if they are not effective	30 (16.7)	149 (82.8)	1 (0.6)
Addiction to narcotic pain killers is likely if narcotic medicine is used for cancer-related pain	18 (10.0)	160 (88.9)	2 (1.1)
If a higher dose of narcotic pain killers is required for cancer-related pain, the probability of addiction increases	6 (3.3)	173 (96.1)	1 (0.6)
Cancer-related pain can be controlled with narcotic pain killers, but the patient’s life span might be reduced as a result	3 (1.7)	173 (96.1)	3 (1.7)
When switching from injected morphine to oral morphine, the dose should remain the same	20 (11.1)	158 (87.8)	2 (1.1)
When tolerance develops for narcotic pain killers, the dose should be reduced or medication should be stopped	11 (6.1)	158 (87.8)	11 (6.1)
Patients should have immediate-release opioids and use them as needed when the pain becomes severe	159 (88.3)	20 (11.1)	1 (0.6)
Narcotic pain killers do not have ceiling effects and the dose can be increased without an upper limit	148 (82.2)	26 (14.4)	5 (2.8)
The use of narcotic pain killers should be reserved for use only when conventional pain killers are no longer effective	2 (1.1)	177 (98.3)	0 (0.0)
Anti-convulsion medicine should be administered additionally for nerve disease-related pain that cannot be controlled to a sufficient level by narcotic pain killers	156 (86.7)	16 (8.9)	7 (3.9)

Day 0	Day −3				Total

	None	Mild	Moderate	Severe
None	191 (75.2)	75 (11.4)	27 (7.8)	3 (2.8)	296 (21.7)
Mild	47 (18.5)	503 (76.6)	139 (40.3)	27 (25.0)	716 (52.5)
Moderate	14 (5.5)	72 (11.0)	152 (44.1)	52 (48.2)	290 (21.3)
Severe	2 (0.8)	7 (1.1)	27 (7.8)	26 (24.1)	62 (4.6)
Total	254 (100)	657 (100)	345 (100)	108 (100)	1,364 (100)

Table 1 Demographic data of cancer patients

SD, standard deviation; ECOG, Eastern Cooperative Oncology Group; MM, multiple myeloma.

Missing data (n=12),

Multiple responses are omitted.

Table 2 Responses to true/false knowledge questionsa)

Values are presented as number (%).

n=180 for doctors who were primary treating patients.

Table 3 Change in pain severity between day .3 and day 0, classified by NRS groupa)